$2.23
+0.00 (+0.00%)
Open$2.28
Previous Close$2.23
Day High$2.29
Day Low$2.19
52W High$5.50
52W Low$1.11
Volume—
Avg Volume495.1K
Market Cap60.96M
P/E Ratio—
EPS$-1.39
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+548.4% upside
Current
$2.23
$2.23
Target
$14.46
$14.46
$8.98
$14.46 avg
$17.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.60M | 19.31M | 20.88M |
| Net Income | -5,133,777 | -5,587,628 | -4,631,912 |
| Profit Margin | -27.6% | -28.9% | -22.2% |
| EBITDA | -5,451,350 | -5,303,939 | -6,015,367 |
| Free Cash Flow | -4,165,501 | -4,081,500 | -5,685,079 |
| Rev Growth | +22.8% | -8.3% | +12.1% |
| Debt/Equity | 0.56 | 0.49 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |